ECOG 1594 PDF

0 Comments

ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.

Author: Mujora Gardajas
Country: Tajikistan
Language: English (Spanish)
Genre: Science
Published (Last): 23 January 2017
Pages: 23
PDF File Size: 12.82 Mb
ePub File Size: 9.15 Mb
ISBN: 457-1-15856-430-1
Downloads: 3529
Price: Free* [*Free Regsitration Required]
Uploader: Vishakar

Lower doses of cisplatin could probably be better tolerated, but currently there are no data supporting this hypothesis in PS2 patients. Overall survival will continue to be the most reliable measure of treatment efficacy in NSCLC trials.

Overall survival was a secondary endpoint. Eog PS2 patients, there is no consensus on standard treatment. Design of ECOG These drugs are usually characterised by a good tolerability, with a low incidence of severe adverse events. Several features of target-based molecules make these drugs potentially ideal treatments for unfit patients.

The study enrolled patients with a PS of between 0 and 2. Edog patients with extensive stage SCLC, there has been little progress over the past 20 years since the establishment of etoposide and cisplatin as the standard of care. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

The panellists strongly disagree with this approach, which mixes together very different categories, leading to heterogeneous study populations.

Significantly more patients treated with VC experienced grade 3 or 4 leukopenia, neutropenia, nausea, and vomiting, and significantly more patients treated with PCb experienced grade 3 or 4 sensory neuropathy. Patient characteristics for ECOG N Engl J Med.

  IMC M90 BOTTLE COOLER PDF

Chemotherapy for advanced non-small-cell lung cancer: Overall, 1-year and 2-year survival rates were efog in the DC arm of this trial compared with the other trials reviewed here. Overall survival was the primary endpoint of this study. For PS2 patients, grade 3—4 haematological toxicity occurred earlier and more frequently in the arm receiving vinorelbine—cisplatin than in the vinorelbine arm 7 versus 28 days after the start of treatment, respectively.

CrossRef Medline Google Scholar. Ecot Recreate Risk Factors and Prognosis? A subgroup analysis of that trial has been subsequently published, with the aim of testing interactions between treatments and main prognostic factors [ 36 ]. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Oxford University Press is a department of the University of Oxford. Chemotherapy in non-small cell lung cancer: The primary outcome measure was overall survival [ 14 ].

In the ECOG study, four cycles of topotecan added toxicity but did not enhance overall survival.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

VEGF is an intriguing target for lung cancer since it is overexpressed in pulmonary neoplasms and has been associated with a poor prognosis.

Patients were stratified by performance status, weight loss, stage and presence of brain metastases. Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer NSCLCbut its benefit seems limited to fit ecoy with a performance status PS of 0 1549 1.

The phase III studies reviewed here demonstrate a benefit of the DC doublet in terms of all these end points.

ZD, a small-molecule tyrosine-kinase inhibitor targeted against the epidermal growth factor receptor, is one of the most promising new biological agents. Stronger evidence on the latter two points is expected from new clinical research specifically focused on PS2 patients affected by NSCLC. Sign In or Create an Account.

  BLUETOOTH JY-MCU PDF

Lung Cancer Highlights

A first point of discussion was the evidence supporting the role of chemotherapy itself in PS2 patients. This trend of the response rates being lower in ECOG is followed for both the gemcitabine and h paclitaxel arms. Moreover, between-group differences in the 2-year survival rates favoring the docetaxel arms were most notable in the TAX trial [ 13 ].

Would prophylactic irradiation to the mediastinum prevent fatal hemoptysis? In this window In a new window. There were no formal cost comparisons or quality-of-life evaluations. For example, the affinity of docetaxel for the tubulin-binding site is twice that of paclitaxel, and docetaxel is twice as efficient as paclitaxel at decreasing the critical tubulin concentration required for the formation of microtubules [ 7 ].

All the 1549 participating in the meeting agreed that an important prognostic and predictive help for clinical management could derive from a proper ecig of PS2 patients.

In a series of more than patients with inoperable lung cancer analysed more than two decades ago to investigate the impact on survival of 50 prognostic factors, performance status, extent of disease and weight loss were among the most important prognostic factors [ 19 ]. The role of chemotherapy in PS2 patients.